Cargando…

Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo

Clostridioides difficile is a leading cause of antibiotic-associated diarrhea and nosocomial infection in the United States. The symptoms of C. difficile infection (CDI) are associated with the production of two homologous protein toxins, TcdA and TcdB. The toxins are considered bona fide targets fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kordus, Shannon L., Kroh, Heather K., Rodríguez, Rubén Cano, Shrem, Rebecca A., Peritore-Galve, F. Christopher, Shupe, John A., Wadzinski, Brian E., Lacy, D. Borden, Spiller, Benjamin W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621975/
https://www.ncbi.nlm.nih.gov/pubmed/37871122
http://dx.doi.org/10.1371/journal.ppat.1011496
_version_ 1785130469444026368
author Kordus, Shannon L.
Kroh, Heather K.
Rodríguez, Rubén Cano
Shrem, Rebecca A.
Peritore-Galve, F. Christopher
Shupe, John A.
Wadzinski, Brian E.
Lacy, D. Borden
Spiller, Benjamin W.
author_facet Kordus, Shannon L.
Kroh, Heather K.
Rodríguez, Rubén Cano
Shrem, Rebecca A.
Peritore-Galve, F. Christopher
Shupe, John A.
Wadzinski, Brian E.
Lacy, D. Borden
Spiller, Benjamin W.
author_sort Kordus, Shannon L.
collection PubMed
description Clostridioides difficile is a leading cause of antibiotic-associated diarrhea and nosocomial infection in the United States. The symptoms of C. difficile infection (CDI) are associated with the production of two homologous protein toxins, TcdA and TcdB. The toxins are considered bona fide targets for clinical diagnosis as well as the development of novel prevention and therapeutic strategies. While there are extensive studies that document these efforts, there are several gaps in knowledge that could benefit from the creation of new research tools. First, we now appreciate that while TcdA sequences are conserved, TcdB sequences can vary across the span of circulating clinical isolates. An understanding of the TcdA and TcdB epitopes that drive broadly neutralizing antibody responses could advance the effort to identify safe and effective toxin-protein chimeras and fragments for vaccine development. Further, an understanding of TcdA and TcdB concentration changes in vivo can guide research into how host and microbiome-focused interventions affect the virulence potential of C. difficile. We have developed a panel of alpaca-derived nanobodies that bind specific structural and functional domains of TcdA and TcdB. We note that many of the potent neutralizers of TcdA bind epitopes within the delivery domain, a finding that could reflect roles of the delivery domain in receptor binding and/or the conserved role of pore-formation in the delivery of the toxin enzyme domains to the cytosol. In contrast, neutralizing epitopes for TcdB were found in multiple domains. The nanobodies were also used for the creation of sandwich ELISA assays that allow for quantitation of TcdA and/or TcdB in vitro and in the cecal and fecal contents of infected mice. We anticipate these reagents and assays will allow researchers to monitor the dynamics of TcdA and TcdB production over time, and the impact of various experimental interventions on toxin production in vivo.
format Online
Article
Text
id pubmed-10621975
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-106219752023-11-03 Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo Kordus, Shannon L. Kroh, Heather K. Rodríguez, Rubén Cano Shrem, Rebecca A. Peritore-Galve, F. Christopher Shupe, John A. Wadzinski, Brian E. Lacy, D. Borden Spiller, Benjamin W. PLoS Pathog Research Article Clostridioides difficile is a leading cause of antibiotic-associated diarrhea and nosocomial infection in the United States. The symptoms of C. difficile infection (CDI) are associated with the production of two homologous protein toxins, TcdA and TcdB. The toxins are considered bona fide targets for clinical diagnosis as well as the development of novel prevention and therapeutic strategies. While there are extensive studies that document these efforts, there are several gaps in knowledge that could benefit from the creation of new research tools. First, we now appreciate that while TcdA sequences are conserved, TcdB sequences can vary across the span of circulating clinical isolates. An understanding of the TcdA and TcdB epitopes that drive broadly neutralizing antibody responses could advance the effort to identify safe and effective toxin-protein chimeras and fragments for vaccine development. Further, an understanding of TcdA and TcdB concentration changes in vivo can guide research into how host and microbiome-focused interventions affect the virulence potential of C. difficile. We have developed a panel of alpaca-derived nanobodies that bind specific structural and functional domains of TcdA and TcdB. We note that many of the potent neutralizers of TcdA bind epitopes within the delivery domain, a finding that could reflect roles of the delivery domain in receptor binding and/or the conserved role of pore-formation in the delivery of the toxin enzyme domains to the cytosol. In contrast, neutralizing epitopes for TcdB were found in multiple domains. The nanobodies were also used for the creation of sandwich ELISA assays that allow for quantitation of TcdA and/or TcdB in vitro and in the cecal and fecal contents of infected mice. We anticipate these reagents and assays will allow researchers to monitor the dynamics of TcdA and TcdB production over time, and the impact of various experimental interventions on toxin production in vivo. Public Library of Science 2023-10-23 /pmc/articles/PMC10621975/ /pubmed/37871122 http://dx.doi.org/10.1371/journal.ppat.1011496 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Kordus, Shannon L.
Kroh, Heather K.
Rodríguez, Rubén Cano
Shrem, Rebecca A.
Peritore-Galve, F. Christopher
Shupe, John A.
Wadzinski, Brian E.
Lacy, D. Borden
Spiller, Benjamin W.
Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo
title Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo
title_full Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo
title_fullStr Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo
title_full_unstemmed Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo
title_short Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo
title_sort nanobodies against c. difficile tcda and tcdb reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621975/
https://www.ncbi.nlm.nih.gov/pubmed/37871122
http://dx.doi.org/10.1371/journal.ppat.1011496
work_keys_str_mv AT kordusshannonl nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo
AT krohheatherk nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo
AT rodriguezrubencano nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo
AT shremrebeccaa nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo
AT peritoregalvefchristopher nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo
AT shupejohna nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo
AT wadzinskibriane nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo
AT lacydborden nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo
AT spillerbenjaminw nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo